Jazz Pharmaceuticals plc (JAZZ) has a P/E ratio of 16.09, below the Healthcare sector average of 25.9.
Get informed when a big investor buys or sells
+ Follow16.09
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Jazz Pharmaceuticals plc posts a P/E ratio of 16.09. That is below the Healthcare sector average of 25.9. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a P/E ratio near 25.9 is typical. Jazz Pharmaceuticals plc's 16.09 is lower that level. That is roughly 37.9% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Jazz Pharmaceuticals plc's P/E ratio of 16.09 comes from dividing a price-based measure by a related financial statistic. Changes can come from the stock price moving, the underlying fundamental shifting, or both. Track both the level and the trend — a rising multiple on falling fundamentals is a different story than a rising multiple on rising earnings.
Context for JAZZ's P/E ratio usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 25.9), and (3) consistency with growth and profitability. This page covers the first two; Jazz Pharmaceuticals plc's other metric pages and overview cover the third.
Judging Jazz Pharmaceuticals plc against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in P/E ratio easier to interpret. Start with 16.09 here, then scan peer and history charts to see if the gap is persistent.